Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: careful (81), measured (540)

Advance care plan: heart conditions - patient information

Description: Advance care planning is an opportunity for you to collect your thoughts and wishes about your future care.
Url: /Media/UHS-website-2019/Patientinformation/Heartandlungs/Advance-care-plan-heart-conditions-3410-PIL.pdf

Finance and Performance Reports 2023-24 Month 6 September 2023

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Finance Report 2023-24 Month 6 12.3 Ian Howard – Chief Financial Of
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-6-September-2023.pdf

BRC NMAHP researcher initiation internship award notes 2023

Description: SoAR researcher initiation award (internship) in collaboration with NIHR BRC Southampton This award is intended to introduce p
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-NMAHP-researcher-initiation-internship-award-notes-2023.pdf

Tepotinib

Description: The Chemotherapy Protocol for Tepotinib, a type of non-small cell lung cancer (NSCLC).
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Tepotinib.pdf

Abiraterone-Prednisolone ver1.1

Description: Chemotherapy Protocol PROSTATE ABIRATERONE-PREDNISOLONE Funding may be required for specific indications Regimen Prostate-Abiraterone-Pr
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Abiraterone-Prednisolone-ver1.1.pdf

Rituximab (3 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (3 Weekly) Regimen Lymphoma – Rituximab (3 weekly) Indication Non Hodgkin’s Lymphoma in combination with chemotherapy Toxicity Dru
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-3-weekly.pdf

FC IV (3 day)-Cyclophosphamide-Fludarabine IV (3 day) Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE–FLUDARABINE INTRAVENOUS (FC IV 3 day) Regimen Lymphoma – FC IV (3 day)- Cyclophospham
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-IV-3-day-Cyclophosphamide-Fludarabine-IV-3-day-Ver-1.1.pdf

Chlorambucil Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CHLORAMBUCIL There are multiple versions of this protocol in use. Please ensure you have the correct protocol for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Chlorambucil-Ver-1.1.pdf

MifamurtideVer1.1

Description: Chemotherapy Protocol SARCOMA MIFAMURTIDE Regimen Sarcoma-Mifamurtide Indication Children, adolescents and young adults (30 years of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/MifamurtideVer1.1.pdf

Cetuximab-Radiotherapy (7 day)

Description: Chemotherapy Protocol HEAD AND NECK CANCER CETUXIMAB RT (7 day) Regimen • Head and Neck Cancer – Cetuximab RT (7 day) Indication •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Cetuximab-Radiotherapy7day.pdf

541 to 550 of 1000

Previous … 53 54 55 56 57 … Next